Accumulating evidence has demonstrated that PD-1/PD-L1 blockade therapy relies on infiltration of tumor-specific cytotoxic T lymphocytes (CTLs) and accumulation of the therapeutic antibodies at tumor sites [5, 6]. This evidence concerns the gene PDCD1 and neoplasm.